ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Autologous TP53 R175H Mutant-specific HLA-A*02:01-restricted TCR Gene Engineered T-lymphocytes NT-175

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by AstraZeneca.

Furthest: phase 1, since May 17, 20231 company-led study, 1 open or runningNext primary completion: Jul 31, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca11 open or runningphase 1since May 17, 2023May 17, 2023Jul 31, 2029phase 1 · NCT05877599
  • Named in AstraZeneca’s own pipeline as NT-175, phase 1, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 17, 2023First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT05877599 · 45 planned · United States

Ahead

  1. Jul 31, 2029Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT05877599

TargetBeta

“A preparation of autologous T-lymphocytes that have been genetically modified to express a T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A*02:01-restricted TP53 (p53) R175H mutant, with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo and r…”NCIt, read by Claude

Other programs on TP53

ProgramCompanyFurthest phaseStudies
Anti-HLA-A*02:01/p53 R175H Bispecific T-cell Engager CLSP-1025ruleclasp-therapeutics-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05877599Carcinoma, Non-Small-Cell Lung · United States1RecruitingJul 31, 202945

How it is read

Names in the registry

  • “NT-175”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.